文档介绍：中国新药与临床杂志
Chinese Journal of New Drugs and Clinical Remedies
ISSN 1007-7669,CN 31-17nemia：enarodustat
LI Geng，BAI Qiu-jiang，ZHU Hui-dong
(Affiliated Taikang Xianlin Drumtower Hospital, Medical College of Nanjing
University，Jiangsu Nanjing 210046, China)
[KEY WORDS] enarodustat；renal insufficiency, chronic；anemia；clinical study
[ABSTRACT] Anemia has a high incidence rate in chronic kidney disease (CKD)
population, and the severity of anemia gradually increases with the decline of renal
function. Enarodustat is another oral hypoxia-inducible factor prolyl hydroxylase
inhibitor followed roxadustat. It was approved in Japan for the treatment of renal
anemia on September 25, 2020. The clinical trials have shown that enarodustat is safe
and effective in the treatment of renal anemia with mild adverse reactions. The
effective dose is only 1 / 10 ~ 1 / 5 of roxadustat, and it can protect the kidney and
reduce cholesterol.
[收稿日期] 2021-01-27 [接受日期] 2022-04-22
[作者简介]李 庚，男，副主任药师，学士，主要从事临床药学的研究，E-mail：*************@。
白秋江，男，主任药师，硕士，主要从事临床药学的研究，E-mail：*************@